Home › Research › Topics › trial
trial
804 studies tagged trial, dated 1986-01-01 to 2026-09-22. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial 2026-09-22
- Varenicline as a Repurposable Drug Candidate for ADRD Prevention 2026-09-20
- Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims 2026-09-17
Studies
804 studies carry this tag.
Date range
1986 to 2026
Top journals
- Neurology 66
- The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 35
- JAMA 24
- JAMA neurology 23
- Alzheimer's research & therapy 21
333 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine.
-
Alzheimer is a disease leading to various neuropsychiatric behavioral disorders, and the most common symptom observed during the prognosis of Alzheimer's disease is dysmnesia.
-
We expect to demonstrate that personalized TMS intervention has a measurable positive impact in cognition, emotion, daily living activities and brain connectivity, thus representing a potential treatment for Alzheimer's disease.
-
Alzheimer's disease is the most common cause of dementia in older people.
-
The present study showed the potential use of IY intervention in reducing stress, anxiety, and depression.
-
A moderate to high intensity aerobic and strength exercise training programme does not slow cognitive impairment in people with mild to moderate dementia.
-
Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the management of dementia.
-
Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was associated with treatment-related adverse events.
-
Although prespecified criteria for testing treatment effects were not met, these data suggest a potential treatment effect in patients with mild AD treated with high-dose crenezumab.
-
The SYNERGIC Trial will establish the efficacy and feasibility of a multimodal intervention to improve cognitive performance and mobility outcomes in MCI.
-
This retrospective cohort study is to investigate the association between herpes simplex virus (HSV) infections and dementia, and the effects of anti-herpetic medications on the risk involved, using Taiwan's National Health Insurance Research Database (NHIRD).
-
We describe the first large-scale, potentially label-enabling clinical trial of a preclinical treatment for ADAD.
-
Description The American College of Physicians developed this guidance statement to guide clinicians in selecting targets for pharmacologic treatment of type 2 diabetes.
-
68/100
Baseline biomarkers largely do not predict risk for developing ARIA-E. ARIA-E was associated with significant longitudinal changes in several biomarkers, with larger reductions in amyloid PET and CSF p-tau and t-tau concentrations, and paradoxically greater hippocampal volume reduction and ventricular enlargement, suggesting that ARIA-E in bapineuzumab-treated cases may be related to increased Aβ efflux from the brain and affecting downstream pathogenic processes.
-
ADAM10 is a metalloproteinase acting on the amyloid precursor protein (APP) as an alpha-secretase in neurons.
-
The plush toy used in this study offered marginally greater value for money than PARO in improving agitation.
-
Additional study of mechanisms of action and methods for titrating stimulation parameters will be needed to determine if DBS has potential as an AD treatment.
-
Dose group efficacy required a significant benefit over placebo for the primary end point and 1 or more key secondary end points.
-
This article primarily describes the design of a monocentre, randomized, doubleblind trial to be conducted in France to evaluate the effect of the combination of tDCS and cognitive training on apathy compared to a group treated exclusively by cognitive training (sham tDCS).
-
Naodesheng (NDS) formula, which consists of Rhizoma Chuanxiong, Lobed Kudzuvine, Carthamus tinctorius, Radix Notoginseng, and Crataegus pinnatifida, is widely applied for the treatment of cardio/cerebrovascular ischemic diseases, ischemic stroke, and sequelae of cerebral hemorrhage, etc. At present, the studies on NDS formula for Alzheimer's disease (AD) only focus on single component of this prescription, and there is no report about the synergistic mechanism of the constituents in NDS formula for the potential treatment of dementia.
-
51/100
Dysbiosis of intestinal microbiota in the elderly can cause a leaky gut, which may result in silent systemic inflammation and promote neuroinflammation - a relevant pathomechanism in the early course of Alzheimer's disease.
-
Defining the primary cognitive endpoint is a major decision for Alzheimer's disease preventive trials.
-
Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles.
-
66/100
Alzheimer's disease (AD) is the most common cause of dementia.
-
The study was stopped early for futility, but dose-dependent effects observed in exploratory analyses on select clinical and biomarker endpoints suggest that higher dosing with gantenerumab may be necessary to achieve clinical efficacy.
-
Alzheimer disease (AD) is one of the most common diseases among the older adults.
-
Alzheimer's disease (AD) is the most prevalent form of dementia.
-
Simvastatin-related reductions in CSF p-tau 181 concentrations may be modulated by LDL cholesterol.
-
Herbal therapy demonstrated a significant improvement in cognition and memory, which were similar to the donepezil in patients with aMCI.
-
42/100
Alzheimer's disease (AD) is the most common neurodegenerative disease.
-
In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment.
-
A novel amyloid β (Aβ) synthetic peptide vaccine (UB-311) has been evaluated in a first-in-human trial with patients of mild-to-moderate Alzheimer's disease.
-
Epidemiological studies have identified a robust association between type II diabetes mellitus and Alzheimer disease (AD), and neurobiological studies have suggested the presence of central nervous system insulin resistance in individuals with AD.
-
Amyloid-β (Aβ) oligomers have been accepted as major neurotoxic agents in the therapy of Alzheimer's disease (AD).
-
Preclinical studies have shown that blueberry supplementation can improve cognitive performance and neural function in aged animals and have identified associations between anthocyanins and such benefits.
-
Aerobic exercise in early AD is associated with benefits in functional ability.
-
This study investigated whether patients with mild to moderately severe dementia or possible Alzheimer's disease (AD) with Mini-Mental State Exam (MMSE) Baseline scores of 10-24 would improve when treated with near-infrared photobiomodulation (PBM) therapy.
-
We included 22 studies involving 43,637 women.
-
Our results suggest that risperidone may affect the CSF profile of AD biomarkers indicating more amyloid pathology.
-
Alzheimer disease (AD) is a most common form of dementia and eventually causes impairments of learning ability and memory function.
-
The MAXCOG intervention is effective in improving goal performance and satisfaction in clients with MCI and early dementia.
-
Bapineuzumab SC once-monthly did not demonstrate significant treatment difference over placebo on cerebral amyloid signal at one year but was well-tolerated.
-
Alzheimer's disease (AD) is the most common type of dementia among the elderly.
-
Deep brain stimulation (DBS) is used to modulate the activity of dysfunctional brain circuits.
-
This study reported the generation of aducanumab, a human monoclonal antibody designed to selectively target aggregated Aβ.
-
Some degree of cognitive decline after surgery occurs in as many as one quarter of elderly surgical patients, and this decline is associated with increased morbidity and mortality.
-
This paper explores the rationale for a mobile phone-led intervention and details the app's effect on behavior change and subsequent clinical outcomes.
-
From both commercial and Medicare Advantage perspectives, mirabegron was the most clinically effective treatment, while oxybutynin was the least expensive.
-
Direct oral anticoagulants (DOACs) have been used in clinical practice in the United States for the last 4 to 6 years.
-
45/100
We report the case of a 73-year-old male patient with Alzheimer's disease who underwent 10-daily transcranial direct current stimulation (tDCS) sessions. tDCS was applied over the left dorsolateral prefrontal cortex as an adjuvant to the traditional treatment that the patient was receiving, which consisted of anticholinergic medication and cognitive training.
From across this tag
9 of the 795 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers
- Rivastigmine for Alzheimer's disease
- Interim biomarker results for trontinemab, a novel Brainshuttle antibody in development for the treatment of Alzheimer's disease
- Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study)
- Feasibility, Safety, and Preliminary Efficacy of Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease: A 12-Month Pilot Randomized Controlled Trial
- Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial
- Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
- L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results
- Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study